Chronic Kidney Disease

WASHINGTON — At ASN Kidney Week, Allena Pharmaceuticals reported positive results from two trials that evaluated reloxaliase in reducing urinary oxalate in patients with enteric hyperoxaluria, as well as in reducing plasma oxalate in those who also have advanced chronic kidney disease.

Compared with “never drinkers,” participants who consumed moderate amounts of alcohol had a lower risk for developing chronic kidney disease, according to published results.

A published study identified six primary themes that may partially explain why patients delay in preparing for dialysis initiation by way of access creation.

Researchers of a published article found that, for African Americans who had both CKD and hypertension, greater urinary sodium excretion was associated with higher blood pressure and larger left ventricular mass.

AstraZeneca announced that the SGLT2 inhibitor dapagliflozin has been granted priority review from the FDA to reduce the risk for CV mortality or worsening HF in patients with HF with reduced ejection fraction with and without type 2 diabetes.

Researchers of a published study observed a worsening of dyslipidemia in proportion to declining GFR, worsening proteinuria and increasing BMI in children with chronic kidney disease.

Published findings suggest that, for patients with chronic kidney disease, a higher dose of sodium bicarbonate lowered urinary ammonium excretion and increased serum bicarbonate more than a lower dose. However, the higher dose was associated with a greater increase in urinary albumin excretion.

An algorithm using data from an electronic health record accurately identified pediatric patients with glomerular disease which, according to published research, may aid in recruitment for observational or prospective studies of the condition.

Published findings determined that, for patients with chronic kidney disease and major depressive disorder, higher concentrations of the inflammatory biomarker hsCRP were associated with both improvement and response to the antidepressant sertraline.

Supplementary vitamin D in low doses may reduce proteinuria in patients with chronic kidney disease, according to results of a nonblinded, non-placebo-controlled study.